Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + interferon α2b
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous, Intramuscular
01
Overview
Bevacizumab + interferon α2b is a combination therapy consisting of two biologic agents used primarily in the treatment of advanced or metastatic renal cell carcinoma (RCC). Bevacizumab is a recombinant humanized monoclonal antibody that binds to and neutralizes vascular endothelial growth factor A (VEGF-A), thereby inhibiting angiogenesis—the formation of new blood vessels necessary for tumor growth. Interferon α2b is a cytokine with immunomodulatory, antiproliferative, and antiangiogenic properties; it inhibits basic fibroblast growth factor (bFGF) and stimulates immune responses against tumor cells. The combination has demonstrated improved progression-free survival compared to monotherapy with interferon in clinical trials for metastatic RCC. It has also been studied in other cancers such as metastatic ocular melanoma[1][2][3][4].
- Other names
- bevacizumab plus interferon α2bbevacizumab and IFN-α2bbevacizumab + IFN-α2b
02
Targets
VEGFA (Vascular endothelial growth factor A)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on bevacizumab + interferon α2b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + interferon α2b.